Profiling of Inflammatory Proteins in Plasma of HIV-1-Infected Children Receiving Antiretroviral Therapy.

Proteomes

Department of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Solnavägen 9, 171 65 Solna, Sweden.

Published: September 2020

Treatment of HIV-1-infected patients results in improved clinical and immunological conditions, but severe non-AIDS-related conditions still persist. Novel proteomic platforms have identified inflammatory proteins where abundance is dysregulated in adult treated patients, whereas limited data are available in treated HIV-1 infection of children. Using a proteomic plasma profiling approach comprising 92 inflammation-related molecules, we analyzed specimens from 43 vertically HIV-1-infected children receiving antiretroviral treatment (ART) and matched controls in Ethiopia. The infected children were analyzed as a group and separately, according to age of treatment initiation. Proteins displaying a significantly different abundance between groups were hierarchically clustered and presented in heat maps. Random forest analysis was performed to pin-point proteins discriminating between groups; five proteins (STAMBP, CD5, TFG-α, TRANCE, AXIN1) were the strongest prediction factors for treated HIV-1 infection. TRANCE was previously linked to reduced bone mass levels in HIV-1-infected children. CCL4 chemokine, ligand to HIV-1 co-receptor CCR5, was the most critical protein for successful classification between children who initiated ART at different time points. Our data provide evidence that a dysregulated expression of proteins linked to immunological abnormalities and bone metabolism can be found in HIV-1-infected children with prolonged exposure to ART.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563605PMC
http://dx.doi.org/10.3390/proteomes8030024DOI Listing

Publication Analysis

Top Keywords

hiv-1-infected children
16
inflammatory proteins
8
children receiving
8
receiving antiretroviral
8
treated hiv-1
8
hiv-1 infection
8
children
7
proteins
6
hiv-1-infected
5
profiling inflammatory
4

Similar Publications

Article Synopsis
  • The study focuses on the envelope glycoprotein (Env) of HIV-1, which is essential for the virus's ability to infect host cells and is a key target for vaccines and therapies.
  • Researchers analyzed the genetic characteristics of the Env gene in 145 newly diagnosed HIV-1 patients in Baoding City, successfully sequencing 142 samples and predicting coreceptor usage.
  • Results indicated that 50% of the patients were infected with CCR5-tropic viruses, and specific subtypes showed trends in coreceptor preferences and similarities in the V3 loop's net charges, enhancing insights for vaccine and treatment development.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how co-occurring HIV and tuberculosis (TB) affect the heart's efficiency in adolescents with HIV acquired at birth (APHIV) in Cape Town, South Africa.
  • Researchers hypothesized that APHIV individuals who had previous TB would show worse cardiovascular health due to increased inflammation and disrupted metabolism.
  • Results indicated that APHIV with prior TB had lower cardiac efficiency compared to those without TB, but this was not linked to traditional markers of inflammation or lipid levels, suggesting other factors may be involved.
View Article and Find Full Text PDF

Background: Despite significant reductions in mother-to-child HIV-1 transmission risks due to the advancements and scale-up of antiretroviral therapy (ART), the global burden of HIV-1 drug resistance (HIVDR) in treatment-naive and treatment-experienced children and adolescents remains poorly understood. In this study, we conducted a systematic review and meta-analysis to estimate the prevalence of HIVDR in these populations globally, regionally, and at the country level.

Methods: We systematically searched PubMed, Embase, and Web of Science for studies reporting HIVDR in treatment-naive and treatment-experienced children and adolescents from inception to June 28, 2024.

View Article and Find Full Text PDF

HIV-1 envelope glycoproteins (Env) from primary HIV-1 isolates typically adopt a pretriggered "closed" conformation that resists to CD4-induced (CD4i) non-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC). CD4-mimetic compounds (CD4mcs) "open-up" Env allowing binding of CD4i nnAbs, thereby sensitizing HIV-1-infected cells to ADCC. Two families of CD4i nnAbs, the anti-cluster A and anti-coreceptor binding site (CoRBS) Abs, are required to mediate ADCC in combination with the indane CD4mc BNM-III-170.

View Article and Find Full Text PDF

Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1.

Bioorg Med Chem Lett

October 2024

State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Sichuan, Chengdu 610041, China. Electronic address:

Article Synopsis
  • Viral infectivity factor (Vif) is a promising target for HIV-1 treatments, and researchers have developed a new class of inhibitors that work well against HIV-1 and its drug-resistant strains.
  • Using proteolytic targeting chimera (PROTAC), the study explores how to effectively degrade the Vif protein, which is crucial for the virus's ability to replicate.
  • The compound L15 has shown a dose-dependent ability to degrade Vif and demonstrated antiviral activity, laying the groundwork for future antiviral drug development using PROTACs for HIV/AIDS.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!